ANNUAL FINANCIAL REPORT 2010 2010 - TiGenix

More documents

Recommendations

Info

D. Trademarks of CellerixThe table below gives an overview of Cellerix’ registered trademark portfolio:Country Trademark Registration number ClassesSpain (Commercial Name) CELLERIX 260.857(X) 5 & 42Europe CELLERIX 4,142,774 5, 10 & 42Spain RETROFECT 2.507.407(5) 35Europe EFISEL 4.68.77.61 10Europe IDRYON 4.68.77.78 10Europe ONTARIL 5,652,599 5Europe MIREDAL 5,652,698 5Europe LIVING MEDICINES 4.67.92.54 16 & 35Europe CELLERIX LIVING MEDICINES 6,879,721 5, 10 & 42Europe ALOCELLIX 7,328,164 3 & 5Europe ADICELL-X 7,328,693 3 & 5Europe CELLERIX (Graphic) 7,335,888 5, 10 & 42Europe ALOFISEL 7,352,081 3 & 5USA CELLERIX (Graphic) 78/920,563 (Registration Pending) 5 & 42USA ONTARIL 77/370,501 (Registration Pending) 5USA CELLERIX LIVING MEDICINES 77/461,497 (Registration Pending) 5 & 42241 •
Appendix 4: BibliographyThe following is a bibliography from which certain information in this prospectus has been derived.2005 Healthpoint Capital Orthopedic Market ReportAlford, J. W. and Cole, B. J. (2005) Cartilage restoration, part 1: basic science, historical perspective, patient evaluation, and treatmentoptions. Am.J.Sports Med. 33: 295-306Alford, J. W. and Cole, B. J. (2005) Cartilage restoration, part 2: techniques, outcomes, and future directions. Am.J.Sports Med. 33: 443-460American Academy of Orthopaedic Surgeons, OA of the Knee – State of the Condition, 2004Arden, N. & Nevitt, M. C.(2006) Best Pract Res Clin Rheumatol, 20(1) 3-25Aroen, A., Loken, S., Heir, S., Alvik, E., Ekeland, A., Granlund, O. G., and Engebretsen, L. (2004) Articular cartilage lesions in993 consecutive knee arthroscopies. Am.J.Sports Med. 32: 211-215Best Pract Res Clin Haematol. 2011 Mar;24(1):49-57. Epub 2011 Feb 23. “Mesenchymal stem cells and autoimmune diseases.”Biotech in Autoimmune/Inflammatory Disease 2006 2nd Edition Arrowhead Publishers.Bongartz, 2009.Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., and Peterson, L. (6-10-1994) Treatment of deep cartilage defects in theknee with autologous chondrocyte transplantation. N.Engl.J.Med. 331: 889-895Brittberg, M. (2008) Autologous chondrocyte implantation--technique and long-term follow-up. Injury 39 Suppl 1: S40-S49Buckwalter, J. A., Saltzman, C., & Brown, T., (2004) The impact of osteoarthritis: Implications for research. Clin. Orthop. Relat. Res (427)Suppl, S6-15.Buckwalter, J. A., Mankin, H. J., and Grodzinsky, A. J. (2005) Articular cartilage and osteoarthritis. Instr.Course Lect. 54: 465-480Burnett, S., Cooper, C., and Spector, T. (1994) A radiographic atlas of osteoarthritis. London: SpringerCicuttini, F., Ding, C., Wluka, A., Davis, S., Ebeling, P. R., and Jones, G. (2005) Association of cartilage defects with loss of knee cartilage inhealthy, middle-age adults: a prospective study. Arthritis Rheum. 52: 2033-2039Clar, C., Cummins, E., McIntyre, L., Thomas, S., Lamb, J., Bain, L., Jobanputra, P., and Waugh, N. (2005) Clinical and cost-effectiveness ofautologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation. Health Technol.Assess. 9: 1-98Curl, W. W., Krome, J., Gordon, E. S., Rushing, J., Smith, B. P., and Poehling, G. G. (1997) Cartilage injuries: a review of 31,516 kneearthroscopies. Arthroscopy 13: 456-460Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. “Intralymphatic immunotherapy.”Senti G, Johansen P, Kündig TM.Cytotherapy. 2007;9(8):755-70. Epub 2007 Oct 4.”Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment ofpediatric cancer.” Dohnal AM, Witt V, Hügel H, Holter W, Gadner H, Felzmann T.Datamonitor, 2009Datamonitor. “Stakeholder Opinions: Autoimmune Diseases in Emerging Markets”. May <strong>2010</strong>.242 • <strong>TiGenix</strong> • Rights Offering
Page 2 and 3:
TiGenix NV(Public limited liability
Page 4 and 5:
Table of ContentsSummary ..........
Page 7 and 8:
3.7.1 Categories of potential inves
Page 9 and 10:
5.7.1 Shares and warrants held by i
Page 11 and 12:
7.5.2 Taxation.....................
Page 13 and 14:
SummaryThe words written in capital
Page 15 and 16:
Activities and strategy of the Comp
Page 17 and 18:
• Two allogeneic adult stem cell
Page 19 and 20:
• TiGenix’ success depends on i
Page 22 and 23:
Unaudited pro forma income statemen
Page 24 and 25:
Recent developmentsAcquisition of C
Page 26 and 27:
In this context, we would like to s
Page 28 and 29:
Announcement of the results of theO
Page 30 and 31:
After the Contribution andafter the
Page 32 and 33:
ContributionContribution AgreementC
Page 34 and 35:
Risk factorsAny investment in the P
Page 36 and 37:
commercialisation of ChondroCelect,
Page 38 and 39:
in delays in bringing products to t
Page 40 and 41:
The Company cannot predict what eff
Page 42 and 43:
y each of its patents and patent ap
Page 44:
to exercise preferential subscripti
Page 47 and 48:
this prospectus which is capable of
Page 49 and 50:
• investment professionals fallin
Page 51 and 52:
1. General information and informat
Page 53 and 54:
1.4.2 Company documents and otherin
Page 55 and 56:
• the granting of discharge of li
Page 57 and 58:
• in case of registered Shares, t
Page 59 and 60:
cast at the meeting. If the amount
Page 61 and 62:
No one may cast a greater number of
Page 63 and 64:
If a Belgian resident individual ne
Page 65 and 66:
Belgium has concluded tax treaties
Page 67 and 68:
3. Information on the Contributiona
Page 69 and 70:
In this context, we would like to s
Page 71 and 72:
TiGenix has a limited financial deb
Page 73 and 74:
Thousands of Euro (€) TiGenix Cel
Page 75 and 76:
3.5.2 Issuance Price and RatioThe i
Page 77 and 78:
(c)Rules for subscriptionSubject to
Page 79 and 80:
The Scrips Private Placement will o
Page 81 and 82:
to comply with any of its obligatio
Page 83 and 84:
3.11.2 Scenario 1: Existing Shareho
Page 85 and 86:
• a pledge of Locked Shares to a
Page 87 and 88:
4. General information about THECOM
Page 89 and 90:
DateINCORPORATIONFebruary 21,2000Tr
Page 91 and 92:
Upon completion of the IPO of TiGen
Page 93 and 94:
Issue dateMay 14,2004April 20,2005T
Page 95 and 96:
4.7.2 Voting rightsAs further descr
Page 97 and 98:
can be obtained free of charge at t
Page 99 and 100:
5.2.4 Composition of the Board of D
Page 101 and 102:
Amonis. Mr. Duron has been CEO of K
Page 103 and 104:
5.3.4 Nomination and remunerationco
Page 105 and 106:
• investor relations: nurturing c
Page 107 and 108:
The remuneration of the members of
Page 109 and 110:
5.7.2 Shares and warrants held by e
Page 111 and 112:
Cellerix EBIP 2010An EBIP for senio
Page 113 and 114:
The minutes must also contain a jus
Page 115 and 116:
6. Activities of Tigenix andits sub
Page 117 and 118:
• Clinical stage pipeline. TiGeni
Page 119 and 120:
6.3.3 Acquisition of CellerixAs a r
Page 121 and 122:
Full thickness articular cartilage
Page 123 and 124:
Fig. 6.2: Autologous Chondrocyte Im
Page 125 and 126:
Preclinical work in a meniscus repa
Page 127 and 128:
The Company is also ensuring high q
Page 129 and 130:
Recognising the importance of pre-l
Page 131 and 132:
In Spain, since the passage of Orde
Page 133 and 134:
Fig. 6.6: ChondroMimetic procedure
Page 135 and 136:
6.5.3 Commercial strategyBuilding o
Page 137 and 138:
6.7 Manufacturing & logisticsEffici
Page 139 and 140:
The international application WO06/
Page 141 and 142:
ChondroMimetic competitionThe main
Page 143 and 144:
in Cellerix’ GMP facility in Madr
Page 145 and 146:
6.14.3 History and development of C
Page 147 and 148:
The table below gives an overview o
Page 149 and 150:
Prevalence No. of cases (2010) Esti
Page 151 and 152:
Fig. 6.9: Platform development stra
Page 153 and 154:
In developing Cx601, Cellerix has b
Page 155 and 156:
6.14.6 Manufacturing & logisticsCel
Page 157 and 158:
population, methods for the isolati
Page 159 and 160:
• Cimzia (certolizumab) - UCB: Al
Page 161 and 162:
Spanish Ministry of Education and S
Page 163 and 164:
7.2 Consolidated income statementTw
Page 165 and 166:
7.3.1.2 Research and development ex
Page 167 and 168:
7.3.2.3 Selling, general and admini
Page 169 and 170:
7.4.1 Cash flows from operating act
Page 171 and 172:
Cash & cash equivalents and intangi
Page 173 and 174:
As of December 31, 2010, the Group
Page 175 and 176:
8. Consolidated Financial informati
Page 177 and 178:
8.1.3 Consolidated cash flow statem
Page 179 and 180:
8.1.5 Notes to consolidated financi
Page 181 and 182:
operating results and operating pla
Page 183 and 184:
The Group does not account for work
Page 186 and 187:
8.1.5.4 Operating result (EBIT)Resu
Page 188 and 189:
8.1.5.7 TaxesThere is no current ta
Page 190 and 191:
8.1.5.10 Tangible assetsThousands o
Page 192 and 193:
8.1.5.14 Deferred charges & accrued
Page 194 and 195:
8.1.5.18 Finance lease obligations
Page 196 and 197:
Business combination Cellerix SADes
Page 198 and 199:
Weighted averageexercise priceTOTAL
Page 200 and 201:
the respective issue date of the wa
Page 202 and 203: Transactions with non-executive dir
Page 204 and 205: 8.1.5.28 Subsequent eventsAcquisiti
Page 206 and 207: 8.1.5.31 Disclosure under Article 1
Page 208 and 209: Additional statementsThe preparatio
Page 210 and 211: 9.1.2 Stand-alone balance sheetYear
Page 212 and 213: 9.1.4 Stand-alone statement of chan
Page 214 and 215: ) Standards and interpretations iss
Page 216 and 217: The clinical development of new dru
Page 218 and 219: future against which they may be ap
Page 220 and 221: Cellerix’ research and developmen
Page 222 and 223: YearThousandsof Euro2010 2009 2008E
Page 224 and 225: Thousands of Euro (€)Laboratoryeq
Page 226 and 227: Current financial assetsShown below
Page 228 and 229: At December 31, Cellerix’ share c
Page 230 and 231: 9.1.5.17 Deferred revenueThe balanc
Page 232 and 233: 9.1.5.21 Share-based paymentsThe EB
Page 234 and 235: GrantsCellerix received several gra
Page 236 and 237: 10. Report regarding unaudited prof
Page 238 and 239: EMAFDAFibrous tissueGCPGMPGrowth fa
Page 240 and 241: Appendix 1: Press releases 2006-201
Page 242 and 243: Appendix 2: REGULATORY APPROVALPROC
Page 244 and 245: like ChondroCelect or the future ce
Page 246 and 247: TitleCountry/regionPatent/applicati
Page 248 and 249: TitleCountry/regionPatent/applicati
Page 250 and 251: Title“Cell populations having imu
Page 254 and 255: Decision resources.Dell’Accio, F.
Page 256 and 257: Noyes, F. R., Barber-Westin, S. D.,
Page 258 and 259: Appendix 5: 2008, 2009 and2010 mana
Page 260 and 261: Contents1. The year in brief ......
Page 262 and 263: 2. Financial informationa. The Inco
Page 264 and 265: The Directors shall call a Sharehol
Page 266 and 267: • Exercise price changed to 5.291
Page 268 and 269: 10 • TiGenix • Rights Offering
Page 274 and 275: Exceptionally, for the following re
Page 276 and 277: (d)(e)Duration: The Options Plan wi
Page 282 and 283: eceipt sent to the number or addres
Page 284 and 285: THE COMPANYTiGenix NVRomeinse straa
show all

ANNUAL FINANCIAL REPORT 2010 2010 - TiGenix

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?